GTBP earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -0.05. Updated 2026-07-23.
GT Biopharma (GTBP) Research Hub
GT Biopharma (GTBP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 8.61 USD (+43.98%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.05, market cap 0.00B. This hub links to the full technical, earnings and options research available for GTBP.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 8.61 USD (+43.98%) |
| 52-week range | 4.91 USD – 13.94 USD |
| Trend regime | Range |
| 14-day RSI | 54.1 (Neutral) |
| Trailing P/E | -0.05 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for GTBP
Covered Call on GTBP: how it works, illustrative setup around the real 8.61 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GTBP: how it works, illustrative setup around the real 8.61 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GTBP: how it works, illustrative setup around the real 8.61 USD price, max profit/loss, breakeven and when to use it. Educational.
GTBP technical analysis: range, last 8.61 USD, RSI 54.1, 52w range 4.91 USD–13.94 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GTBP in?
GT Biopharma (GTBP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GTBP in an uptrend or downtrend?
As of 2026-09-11, GTBP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GTBP's trailing P/E ratio?
GTBP's trailing P/E is -0.05, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does GTBP next report earnings?
GTBP is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.08 USD.